Keywords: Ebf1 Osteoblast Bone mass a b s t r a c t Early B-cell factor 1 (Ebf1) is a transcription factor whose inactivation in all cells results in high bone mass because of an increase in bone formation. This observation suggests Ebf1 may be an inhibitor of osteoblast differentiation. To test this contention, we analyzed Ebf1 pattern of expression and function in osteoblasts ex vivo and in vivo through osteoblast-specific inactivation in the mouse. We show here that in vivo deletion of Ebf1 in osteoblast progenitors does not affect osteoblast differentiation or bone formation accrual post-natally. These observations indicate that the phenotype described in Ebf1 À/À mice is not osteoblast-autonomous.
Introduction
Our understanding of the transcriptional control of the differentiation processes that generate, during embryonic development, the various cell types of mesenchymal origin, i.e., the osteoblast, chondrocyte, myoblast, and adipocyte, has made considerable progress during the past two decades. Although these cell types derive from a common progenitor, the mesenchymal stem cell (MSC), their differentiation along various lineages depends on distinct sets of transcription factors. In particular, the early steps of differentiation of MSCs to osteoblasts require the function of Runx2, while later steps of differentiation involve at least two other transcription factors, Osterix and Atf4 [1] .
Besides the cardinal transcription factors mentioned above, many others have been shown to affect osteoblast differentiation either by modulating Runx2 activity or by functioning independently of Runx2. Twist and Schnurri-3 are two examples of the former [2, 3] , while members of the AP-1 family and Creb act independently of Runx2 to affect osteoblast differentiation and proliferation [4, 5] . Another factor for which mouse genetics has given clear indications that it contributes to osteoblast phenotype is Ebf1.
Early B-cell factor 1 (Ebf1) is a member of a small family of transcription factors that contains an atyptical zinc finger DNA binding domain and a non-basic helix-loop-helix (HLH) dimerization domain [6] . Originally cloned as a putative B-cell transcription factor, Ebf1 was confirmed by loss-of-function experiments in the mouse to be a pioneer factor essential for the commitment and maintenance of B-cell fate [6, 7] . The cell differentiation ability of Ebf1 has been expanded to neurons of the embryonic striatum during mouse development [8] . More recently, two indirect but convergent lines of evidence raised the prospect that Ebf1 may prevent osteoblast differentiation and instead favor allocation of MSCs toward the adipocyte lineage.
First, in the pre-adipogenic 3T3L1 cell line Ebf1 promotes PPARc expression, while reducing Ebf1 expression inhibits the adipocyte differentiation potential of this cell line [9, 10] . Second, and more importantly for our purpose, analysis of mice lacking Ebf1 in all cells revealed a marked increase in the number of osteoblasts and in bone formation parameters [11, 12] . This experiment established Ebf1 as a negative regulator of osteoblast differentiation. As importantly, that this high bone mass phenotype was observed in mice lacking Ebf1, but not other members of this small family of transcription factors, indicated that there was no overt redundancy between Ebf1 and other members of the Ebf family when it comes to the regulation of osteoblast differentiation.
In view of the strong phenotype of Ebf1 À/À mice and of Ebf1 differentiation ability in other cell lineages, it is legitimate to suspect that Ebf1 inhibits osteoblast differentiation in a cell-autonomous manner. To determine if this is indeed the case we relied on Ebf1 knockdown in cell culture and the analysis of mutant mice lacking Ebf1 only in cells of the osteoblast lineage. To our surprise, Ebf1 deletion in cells of the osteoblast lineage throughout development and after birth has no overt deleterious consequences on the differentiation of osteoblasts, bone formation parameters, or overall bone mass accrual. Taken at face value, these observations identify Ebf1 as one of the few transcription factors inhibiting osteoblast differentiation in a non cell-autonomous manner.
Materials and methods

Mice generation
Ebf1
fl/+ mice were generated as previously described [13] . To generate osteoblast-specific Ebf1 deficient mice, Ebf fl/fl mice were crossed with Ebf1 fl/+ ; Runx2-Cre mice, which were then crossed to Ebf fl/fl mice to generate Ebf1 osb À/À mice. Genotypes of mice were determined by PCR. Primer sequences are available upon request. All mice were 1-month old males maintained on the C57BL/6 genetic background.
In situ hybridization
Embryos were fixed in 4% paraformaldehyde and embedded in paraffin. Radioactive in situ hybridization was performed on 6 lm sections using 35 S-labeled riboprobes. Hybridizations were performed overnight at 55°C, and washes were performed at 63°C. Autoradiography and Hoechst 33528 staining were performed as described [14] . Probe sequences available upon request.
Immunohistochemistry
Embryos were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at 7 lm. Immunohistochemistry was performed using an immunoperoxidase system (ABC Elite Kit, Vector Laboratories) with anti-Neun (Millipore) or a monoclonal rat anti-Ebf1 antibody that was previously characterized [13] . Nova Red was used to localize peroxidase.
Molecular studies
RNA isolation and quantitative PCR were performed following standard protocols.
Statistical analysis
Results are given as means ± standard error of means unless otherwise indicated. Statistical analyses were performed using the Student's t-test.
Cell culture
Primary osteoblasts were cultured and differentiated as previously described [15] . Cells were transfected with siRNA pools (on-TARGETplusSMARTpool, Dharmacon) according to manufacturer instructions. Ebf1 +/+ or Ebf1 À/À osteoblasts were generated by infecting Ebf1 fl/fl osteoblasts with either green fluorescent protein (GFP)-or Cre-expressing adenovirus (University of Iowa).
Chromatin immunoprecipitation (ChIP)
10T1/2 cells were harvested and resuspended in medium at a concentration of 1 to 2 Â 10 6 cells/ml. Crosslinking mix (11% formaldehyde, 100 mM NaCl, 0.5 mM EGTA, 1 mM EDTA, 50 mM Hepes, pH 8.0) was added to a final concentration of 1% formaldehyde. Crosslinking reaction was stopped after 10 min at room temperature by the addition of glycine to a final concentration of 125 mM. Cells were spun down immediately and washed three times with ice cold PBS. They were resupended in lysis buffer (1.25% SDS, 12.5 mM EDTA, 62.5 mM Tris-HCl, pH 8.0, protease inhibitor mix) with a concentration of 20 to 40 Â 10 6 cells/ml. With a Bioruptor Ò Standard the chromatin was sheared into pieces of 300-500 bp. This chromatin was stored at À80°C and subsequently used for ChIP experiments.
The Ebf1 antibody used is a polyclonal rabbit anti Ebf1 antibody that detects the N-terminus of b-Ebf1 that was previously characterized [13] . 4 lg of an anti-murine Ebf1 antibody or normal rabbit IgG (Millipore 12-370) was added for each ChIP. 100 ll chromatin were diluted 1:10 in dilution buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 200 mM NaCl, 0.5% NP-40, protease inhibitor mix).
Samples were rotated for 16-20 h at 4°C and washed. Protein-A Sepharose beads were added for another two hours. Subsequently beads were washed five times with wash buffer (0.1% SDS, 1% NP-40, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl, pH 8.0) and four times with TE buffer (10 mM Tris-HCl pH8, 1 mM EDTA pH 8.0).
Immunoprecipitated chromatin was eluted two times with 50 ll elution buffer (2%SDS, 10 mM Tris-HCl pH 8, 1 mM EDTA pH8.0) for 10 min at 65°C shaking. Elutions were pooled and decrosslinked for at least 6 h at 65°C. DNA was finally purified with QIAquick Ò PCR Purification Kit (Qiagen Cat. No.28106). The purified DNA was used in quantitative PCR to analyze binding of Ebf1 to DNA. Negative controls include chr. II, Pax5, cd79a, CD40, Igll1. Positive control is Pcgf1.
Histology
Static and dynamic histomorphetric analyses were performed on vertebral column specimens collected from 1-month old mice using undecalcified sections according to standard protocols, and using the Osteomeasure analysis system (Osteometrics).
Results
Ebf1 is expressed at low levels in osteoblasts during embryonic development
At the onset of this study and to guide our investigation, we sought to determine which members of the Ebf family were the most highly expressed in primary osteoblasts. qPCR analysis using exonic primers normalized to genomic DNA revealed that in osteoblasts, Ebf1 was clearly more abundantly expressed than the other three members of the Ebf family. In cells that were fully differentiated, this difference in level of expression was at least one order of magnitude (Fig. 1A) . Given this result and the important fact that deletion of Ebf1 in all cells suffices to affect bone mass accrual, we thus focused the remainder of our analysis on the function Ebf1 may have in osteoblasts.
We then studied the Ebf1 pattern of expression in the developing skeleton by in situ hybridization. As previously shown, the marker of bone formation, Runx2, is robustly expressed in osteoprogenitors of the developing ribs already at E12.5 [16] . In contrast, in an adjacent section, the expression of Ebf1 in osteoprogenitors, although detectable, was significantly weaker (Fig. 1B) . Similarly, at E14.5 and E16.5, expression of Runx2 in cells of the osteoblast lineage was quite high, but expression of Ebf1 remained barely above the limit of detection (Fig. 1B) . Finally, we compared the expression of Ebf1 in adult tissue, and also observed rather low expression in bone and cartilage (Fig. 1C) . In summary, these results indicate that Ebf1 expression does not appear as early as Runx2 and is less pronounced than the one of Runx2 during skeletogenesis, suggesting that Ebf1 may not have a critical role in the osteoblast even though Ebf1 À/À mice have high bone mass [11] . Of note, we also investigated the expression pattern of Ebf1 in other cell types through immunohistochemistry performed in the embryo at different stages of development. This analysis revealed high levels of Ebf1 in the dorsal root ganglia and spinal cord, marked in an adjacent section by a pan-neuronal antibody NeuN (Fig. 1D ).
Ebf1 affects osteoblast gene expression ex vivo
Next, to determine whether or not Ebf1 may be a cell-autonomous molecular suppressor of osteoblast differentiation, we analyzed the effects of siRNA-mediated down-regulation of Ebf1 mouse osteoblasts that were transfected with a siRNA to transiently suppress Ebf1 expression but not affect Ebf2, 3, or 4 expression ( Fig. 2A) .
For that purpose, primary osteoblasts from calvaria of newborn mice were transfected with Ebf1 siRNA, resulting in a 76% decrease in Ebf1 expression. We also confirmed that the siRNA we used was specifically targeting Ebf1, and did not result in altered expression of Ebf2, 3, or 4 ( Fig. 2A) . Ebf1 knockdown in primary osteoblasts increased expression of Osterix, Col1a1, Osteocalcin, and Alkaline phosphatase (Alpl). These results were certainly consistent with the notion that Ebf1 acts as a cellautonomous inhibitor of osteoblast differentiation. Of note, within the conditions of this experiment, we did not observe any change in the expression of adipocyte-specific transcription factors such as PPARc, C/EBPa, C/EBPb (Fig. 2A) .
In view of these results we asked whether Ebf1 directly binds to some of the genes whose expression was perturbed by its knockdown in the above-mentioned experiment. With the help of a genome-wide data set of an Ebf1 ChIPseq experiment, performed in the murine bone marrow stroma cell line OP-9 (Boller et al. unpublished data), we could identify potential Ebf1 binding sites. We further validated these sites by quantitative ChIP using the multipotent mesenchymal cell line 10T1/2, which expresses Ebf1 (Supplementary Fig. 1 ). This analysis indicated that Ebf1 binds at multiple sites in the Alpl and Osterix regulatory regions (Fig. 2B) .
Ebf1-independent osteoblast differentiation in vivo
In view of this encouraging set of ex vivo observations, we next studied the function of Ebf1 specifically in osteoblasts in vivo and crossed Ebf1 fl/fl mice with mice expressing Cre recombinase under the control of the Runx2 regulatory elements [17] . We chose Runx2-Cre mice to address this question, as Runx2 is the earliest and also the most specific molecular marker of the osteoblast lineage identified to date [16] . Hence, this Cre driver would allow us to study Ebf1 function in cells of the osteoblast lineage at each stage of differentiation. Prior to analyzing these mice, we verified that we had achieved efficient deletion of Ebf1 in osteoblasts. Ebf1 was decreased by 80% in whole bone, and by more than 95% in osteoblasts derived from bone marrow. Although Ebf1 expression was also reduced in cartilage, its expression was not affected in the other tissues tested (Supplementary Fig. 2 ). Ebf1 osb À/À mice were born at the expected Mendelian ratio, had normal life expectancy, and appeared overall normal, indicating that its expression in Runx2-expressing cells is dispensable for normal embryonic development. Body weight, epididymal fat pad weight, body and femoral lengths were similar between ,and Runx2-Cre mice) (Fig. 3A) . To our surprise, bone histomorphometric analysis performed in vertebrae of 1-month old Ebf1 osb À/À and control mice did not reveal any change in osteoblast number, bone formation rate, and bone mass (Fig. 3B) . Serum osteocalcin levels were similarly unaffected in Ebf1 osb À/À mice (Fig. 3C) . Gene expression analysis performed in bone tissue did not record any of the changes in gene expression that had been observed in cell culture experiments (Fig. 3D ). This set of observations indicates that in vivo, Ebf1 does not negatively regulate osteoblast differentiation through its expression in cells of the osteoblast lineage.
To perform a complete analysis of Ebf1 function in osteoblasts, we cultured Ebf1 À/À osteoblasts. Ex vivo, Ebf1 À/À osteoblasts form less mineralization nodules and produce slightly less alkaline phosphatase ( Fig. 4A and B) , though they display no significant change in Alpl or Osterix expression (Fig. 4C) . This result contrasts with the fact that in vivo, Ebf1 osb À/À bones have no mineralization defect (Fig. 3B) . In an effort to further explore the significance of this ex vivo observation, we also stably overexpressed Ebf1 (approximately 40% increase) in MC3T3-E1 cells that can mineralize in culture [18] (Fig. 4D) . Through this Ebf1 overexpression, we observed an increase in extracellular matrix mineralization (Fig. 4E ).
Discussion
Previous observations stemming from cell culture experiments and from the analysis of mice lacking Ebf1 in all cells had indicated that Ebf1 is a negative regulator of osteoblast differentiation and bone formation [9] [10] [11] . These data immediately raised the question of whether Ebf1 acts in a cell-autonomous manner to fulfill this function. This is an even more important question given the fact that among all members of this small family of transcription factors, Ebf1 is the most highly expressed in cells of the osteoblast lineage by far.
Transient Ebf1 loss of function experiments performed in primary osteoblasts fully supported the notion that Ebf1 negatively regulates osteoblast-specific gene expression. Since expression of important genes for the osteoblast phenotype such as Osterix, Col1a1, Osteocalcin, and Alpl were increased in cells lacking Ebf1, these results were fully consistent with the high bone mass observed in Ebf1 À/À and suggested that Ebf1 acts in a cellautonomous manner to regulate osteoblast differentiation.
Hence, it came as a surprise that cell-specific Ebf1 deletion in cells of the osteoblast lineage in the mouse does not have any overt consequences on osteoblast differentiation in vivo. Results of this analysis in Ebf1 osb À/À mouse model are surprising for several reasons. The first reason is that the in vivo results have no clear relationship to what was previously observed in cell culture by others and by us, after a decrease of Ebf1 expression in differentiated osteoblasts [9, 10] . As such, these results illustrate how cautious one should be when making inference about the differentiation ability of a given transcription factor or of any other regulatory gene based on cell culture assays alone. This result was even less expected given the fact that Ebf1 binding sites are present in such an important regulator of osteoblast differentiation as Osterix. Last, but not least, these results were also unanticipated because they are not consistent with what has been observed in mice globally lacking Ebf1, which display high bone mass with a concomitant decrease in adiposity [11] . Although the formal possibility remains that Ebf1 function is masked by the remaining expression of Ebf2, 3, and 4, we note that mice lacking Ebf1 in all cells present cell differentiation defects even though other Ebfs are normally expressed. Thus we believe this is an unlikely possibility [19] . At the present time the most likely interpretation of the unanticipated results presented here is that the phenotype observed previously in Ebf1 À/À mice may be due to a cell-nonautonomous defect. These results indicate that Ebf1 belongs to a class of transcriptional regulators of osteoblast differentiation that act in a non cellautonomous manner. Possible areas where Ebf1 may function to regulate bone mass include the dorsal root ganglia and spinal cord where Ebf1 is highly expressed.
Overall this study underscores how informative a cell-specific deletion approach is to study gene function. Indeed, the lack of a bone phenotype in Ebf1 osb À/À mice contrasts sharply with the bone phenotype of Ebf1 À/À mice, but is in agreement with the weak expression of Ebf1 in osteoblasts. Our experiments also indicate that even for processes such as extracellular matrix mineralization, results can differ between ex vivo and in vivo approaches. Hence, they suggest that an ex vivo approach only is not enough to study the role of a given gene in extracellular matrix mineralization. The reasons for this discrepancy will need to be further addressed.
